NYX

Nyctalopin (NYX) is a GPI-anchored small leucine-rich proteoglycan expressed on the surface of retinal ON-bipolar cells, where it is essential for depolarizing (ON) bipolar cell signal transmission in the rod and cone pathways (PMID:11062471, PMID:15331616). The protein is targeted to the plasma membrane via an N-terminal signal peptide and a C-terminal GPI anchor; deletion of either domain disrupts surface localization (PMID:14507859). Loss-of-function mutations in NYX abolish signal transmission through the rod bipolar–AII amacrine cell (slow rod) pathway while sparing residual rod-cone gap junction signaling, and cause X-linked complete congenital stationary night blindness (CSNB1) (PMID:11062471, PMID:11581222). In Nyx-null mice, the ON-pathway deficit leads to oscillatory retinal ganglion cell activity and desegregated retinogeniculate projections, indicating that nyctalopin-dependent ON signaling shapes downstream visual circuit organization (PMID:35328623).

1. 2000 High

   Positional cloning identified NYX as the gene mutated in X-linked complete CSNB (CSNB1), establishing that this GPI-anchored leucine-rich proteoglycan is required for normal ON-pathway retinal signaling.

   Evidence Positional cloning and mutation screening across 22 families identifying 14 independent loss-of-function mutations

   PMID:11062471

   Open questions at the time

   • Molecular mechanism by which nyctalopin supports ON-pathway signaling unknown
   • Cell-type-specific expression within the retina not yet resolved
   • No direct protein interaction partners identified
2. 2001 High

   ERG pathway dissection in CSNB1 patients showed that nyctalopin is specifically required for the rod bipolar–AII amacrine (slow rod) pathway, while the rod-cone gap junction (fast rod) pathway remains functional, localizing the defect to ON bipolar cell signaling rather than photoreceptor function.

   Evidence Scotopic 15 Hz flicker ERG at multiple intensities in 11 genetically confirmed NYX-mutant patients versus 22 controls

   PMID:11581222

   Open questions at the time

   • Whether the defect is in synaptic input, intrinsic bipolar cell physiology, or both is unresolved
   • Cone ON-bipolar cell involvement not separately tested
3. 2003 High

   Subcellular localization studies demonstrated that nyctalopin reaches the plasma membrane via its GPI anchor and signal peptide; pathogenic LRR-region mutations do not alter trafficking, implying these mutations disrupt an extracellular interaction rather than protein localization.

   Evidence V5-tagged wild-type and mutant NYX constructs expressed in COS-7 and HeLa cells with sequential live-cell surface and intracellular staining, plus deletion mutagenesis

   PMID:14507859

   Open questions at the time

   • Identity of the extracellular interaction partner(s) of the LRR domain remains unknown
   • Surface localization shown in heterologous cells, not retinal neurons
4. 2003 High

   In situ hybridization and immunohistochemistry localized Nyx expression to the inner nuclear layer and ganglion cell layer throughout postnatal retinal development, consistent with a role in inner retinal (bipolar/ganglion cell) circuitry.

   Evidence RT-PCR, RNA in situ hybridization, and IHC with Nyx-specific antibodies in mouse and rat retinas across developmental stages

   PMID:12714669

   Open questions at the time

   • Whether expression in ganglion cells is functionally relevant or incidental is unclear
   • Protein-level localization to specific subcellular compartments within bipolar cells not resolved
5. 2004 High

   Pharmacological blockade of ON-bipolar cells with APB in primates fully recapitulated CSNB1 ERG abnormalities, providing epistatic evidence that nyctalopin acts principally or exclusively at the depolarizing (ON) bipolar cell level.

   Evidence Intravitreal APB and PDA injections in anesthetized non-human primates with ERG comparison to genotyped CSNB1-NYX human patients

   PMID:15331616

   Open questions at the time

   • Whether nyctalopin acts upstream (e.g., at the mGluR6 signaling complex) or downstream within the ON-bipolar cell is unresolved
   • Direct physical or signaling relationship between nyctalopin and the mGluR6/TRPM1 cascade not tested
6. 2006 Medium

   nyx regulatory sequences drive expression specifically in ON-bipolar cells in vivo, and live imaging of nyx-expressing bipolar axon terminals revealed a developmental sequence of filopodial exploration followed by bouton stabilization.

   Evidence Transgenic zebrafish expressing MYFP under nyx regulatory elements; time-lapse confocal and two-photon imaging

   PMID:17020638

   Open questions at the time

   • This reports promoter activity, not protein function; nyctalopin's role in axon terminal development is not directly tested
   • Cross-species relevance to mammalian ON-bipolar cell development not confirmed
7. 2022 Medium

   Nyx-null mice exhibit oscillatory ganglion cell firing and expanded, desegregated retinogeniculate projections, demonstrating that loss of ON-pathway signaling through nyctalopin has circuit-level consequences beyond the bipolar cell.

   Evidence Multi-electrode array recordings of retinal ganglion cell receptive fields in Nyx mutant versus wild-type mice

   PMID:35328623

   Open questions at the time

   • Whether the circuit remodeling is a direct consequence of absent ON signaling or involves a separate developmental role of nyctalopin is not distinguished
   • Single study; independent replication in a second model system not available

• The direct molecular interaction partners of nyctalopin's extracellular LRR domain — and the mechanism by which it enables ON-bipolar cell depolarization (e.g., interaction with TRPM1, GRM6, or another transduction component) — remain unidentified from the discovery timeline.
• No binding partner for the LRR domain identified
• Relationship to TRPM1/mGluR6 signaling complex not directly tested
• No structural model of nyctalopin available